We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Recipharm Signs Partnership Agreement with Follicum
News

Recipharm Signs Partnership Agreement with Follicum

Recipharm Signs Partnership Agreement with Follicum
News

Recipharm Signs Partnership Agreement with Follicum

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Recipharm Signs Partnership Agreement with Follicum"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Recipharm has announced that it has signed a partnership agreement with Follicum AB in preparation for a clinical trial of the drug candidate FOL-005.

Recipharm has been engaged to formulate and produce the product that will be used in the clinical trial. The engagement also includes developing and validating the analytical methods required.

“Preparations for the clinical study are well under way, and we have now established ties with partners that we feel confident in. Recipharm is successful in its field and has a strong track record. We look forward to the finished product, which is expected to be ready at the end of the year, in time for the launch of the clinical study,” says Jan Alenfall, CEO of Follicum.

“We have extensive experience in the development of pharmaceuticals for clinical trials and are very excited to be able to contribute to the development of this product,” says Maria Lundberg, General Manager of Recipharm in Solna.

Advertisement